Table 2:

Treatment-related AEs occurring in at least 5% of patients in the eganelisib + nivolumab combination therapy cohort^a

n (%)	Eganelisib dose escalation + nivolumab (Part C)						Eganelisib + nivolumab dose expansion (Parts E-H: eganelisib 40 mg) (n=149)
	20 mg (n=7)		30 mg (n=12)		40 mg (n=12)
	Any grade	G≥3	Any grade	G≥3b	Any grade	G≥3c	Any grade	G≥3d
Any treatment-related TEAE	4 (57)	1 (14)	9 (75)	4 (33)	9 (75)	5 (42)	110 (74)	58 (39)
Rashe	1 (14)	1(14)	5 (42)	1 (8)	8 (67)	3 (25)	77 (52)	21 (14)
AST increased			1 (8)	-	5 (42)	5 (42)	39 (26)	21 (14)
ALT increased			1 (8)	-	5 (42)	4 (33)	36 (24)	16 (11)
Fatigue					2 (17)	-	28 (19)	-
Nausea	1 (14)	-	1 (8)				21 (14)	2 (1)
Pyrexia			1 (8)	-	1 (8)	-	21 (14)	2 (1)
Blood ALP increased					2 (17)	-	13 (9)	6 (4)
Decreased appetite							12 (8)	-
Diarrhea			2 (17)	-	1 (8)	-	9 (6)	1 (1)
Vomiting	1 (14)	-	1 (8)	-	1 (8)	-	9 (6)	2 (1)
Chills							10 (7)	1 (1)
Arthralgia							9 (6)	-
Myalgia							9 (6)	-
Lipase increased			1 (8)	1 (8)	1 (8)	-	8 (5)	2 (1)

Abbreviations: ALT, alanine aminotransferase; AST, alanine aminotransferase; ALP, alkaline phosphatase; G≥3, grade 3 or higher; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent adverse event.

^aEganelisib was administered once daily and nivolumab as 240 mg Q2W or 480 mg Q4W.

^bGrade 3 events of dermatitis acneiform (n=1) and joint effusion (n=1) not shown.

^cAll events were grade 3 except for grade 4 ALT increased (n=1). Grade 3 event of abdominal pain (n=1) not shown.

^dAll events were grade 3 except for grade 4 AST increased (n=1), transaminases increased (n=1), and lymphocyte count decreased (n=1).

^eIncludes preferred terms pruritis, rash, rash macular, and rash maculopapular.